Carcinoma, Renal Cell

"Carcinoma, Renal Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.

Descriptor ID	D002292
MeSH Number(s)	C04.557.470.200.025.390 C04.588.945.947.535.160 C12.758.820.750.160 C12.777.419.473.160 C13.351.937.820.535.160 C13.351.968.419.473.160
Concept/Terms	Carcinoma, Renal Cell Carcinoma, Renal Cell Carcinomas, Renal Cell Renal Cell Carcinomas Adenocarcinoma, Renal Cell Adenocarcinomas, Renal Cell Renal Cell Adenocarcinoma Renal Cell Adenocarcinomas Adenocarcinoma Of Kidney Adenocarcinoma Of Kidneys Kidney, Adenocarcinoma Of Kidneys, Adenocarcinoma Of Renal Cell Cancer Cancer, Renal Cell Cancers, Renal Cell Renal Cell Cancers Adenocarcinoma, Renal Adenocarcinomas, Renal Renal Adenocarcinoma Renal Adenocarcinomas Nephroid Carcinoma Carcinoma, Nephroid Carcinomas, Nephroid Nephroid Carcinomas Renal Cell Carcinoma Chromophobe Renal Cell Carcinoma Chromophobe Renal Cell Carcinoma Sarcomatoid Renal Cell Carcinoma Sarcomatoid Renal Cell Carcinoma Papillary Renal Cell Carcinoma Papillary Renal Cell Carcinoma Renal Cell Carcinoma, Papillary Chromophil Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma Grawitz Tumor Tumor, Grawitz Clear Cell Renal Carcinoma Carcinoma, Hypernephroid Carcinomas, Hypernephroid Hypernephroid Carcinoma Hypernephroid Carcinomas Hypernephroma Hypernephromas Collecting Duct Carcinoma (Kidney) Collecting Duct Carcinoma (Kidney) Carcinoma, Collecting Duct (Kidney) Carcinomas, Collecting Duct (Kidney) Collecting Duct Carcinomas (Kidney) Collecting Duct Carcinoma of the Kidney Renal Collecting Duct Carcinoma Collecting Duct Carcinoma Carcinoma, Collecting Duct Carcinomas, Collecting Duct Collecting Duct Carcinomas

Below are MeSH descriptors whose meaning is more general than "Carcinoma, Renal Cell".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Neoplasms, Glandular and Epithelial [C04.557.470]
Carcinoma [C04.557.470.200]
Adenocarcinoma [C04.557.470.200.025]
Carcinoma, Renal Cell [C04.557.470.200.025.390]
Neoplasms by Site [C04.588]
Urogenital Neoplasms [C04.588.945]
Urologic Neoplasms [C04.588.945.947]
Kidney Neoplasms [C04.588.945.947.535]
Carcinoma, Renal Cell [C04.588.945.947.535.160]
Male Urogenital Diseases [C12]
Urogenital Neoplasms [C12.758]
Urologic Neoplasms [C12.758.820]
Kidney Neoplasms [C12.758.820.750]
Carcinoma, Renal Cell [C12.758.820.750.160]
Urologic Diseases [C12.777]
Kidney Diseases [C12.777.419]
Kidney Neoplasms [C12.777.419.473]
Carcinoma, Renal Cell [C12.777.419.473.160]
Female Urogenital Diseases and Pregnancy Complications [C13]
Female Urogenital Diseases [C13.351]
Urogenital Neoplasms [C13.351.937]
Urologic Neoplasms [C13.351.937.820]
Kidney Neoplasms [C13.351.937.820.535]
Carcinoma, Renal Cell [C13.351.937.820.535.160]
Urologic Diseases [C13.351.968]
Kidney Diseases [C13.351.968.419]
Kidney Neoplasms [C13.351.968.419.473]
Carcinoma, Renal Cell [C13.351.968.419.473.160]

Below are MeSH descriptors whose meaning is related to "Carcinoma, Renal Cell".

Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Renal Cell".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Carcinoma, Renal Cell" by people in this website by year, and whether "Carcinoma, Renal Cell" was a major or minor topic of these publications.

Bar chart showing 110 publications over 24 distinct years, with a maximum of 17 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	1	0	1
1996	1	0	1
1997	1	0	1
1998	1	0	1
2000	1	0	1
2002	1	0	1
2003	3	0	3
2004	1	1	2
2005	5	0	5
2006	4	0	4
2008	2	0	2
2009	1	0	1
2012	1	0	1
2013	4	1	5
2014	6	1	7
2015	8	0	8
2016	6	1	7
2017	7	0	7
2018	11	0	11
2019	10	0	10
2020	6	0	6
2021	17	0	17
2022	7	0	7
2023	1	0	1

Below are the most recent publications written about "Carcinoma, Renal Cell" by people in Profiles.

Khan SY, Snitman A, Habrawi Z, Crawford S, Melkus MW, Layeequr Rahman R. ASO Visual Abstract: The Role of Cryoablation in Breast Cancer Beyond the Oncologic Control: COST and Breast-Q Patient Reported Outcomes. Ann Surg Oncol. 2023 02; 30(2):1040-1041.

View in: PubMed
Molina-Cerrillo J, Santoni M, Ruiz ?, Massari F, Pozas J, Ortego I, G?mez V, Grande E, Alonso-Gordoa T. Epigenetics in advanced renal cell carcinoma: Potential new targets. Crit Rev Oncol Hematol. 2022 Dec; 180:103857.

View in: PubMed
Santoni M, Molina-Cerrillo J, Myint ZW, Massari F, Buchler T, Buti S, Matrana MR, De Giorgi U, Rizzo M, Zabalza IO, Galli L, Zucali PA, Aurilio G, Incorvaia L, Bassanelli M, Mammone G, Salfi A, Isella L, Mollica V, Grande E, Porta C, Battelli N. Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies. Target Oncol. 2022 09; 17(5):571-581.

View in: PubMed
Santoni M, Massari F, Matrana MR, Basso U, De Giorgi U, Aurilio G, Buti S, Incorvaia L, Rizzo M, Martignetti A, Maslov D, Tawagi K, Philon E, Blake Z, Porta C, Battelli N. Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. Eur J Cancer. 2022 09; 172:191-198.

View in: PubMed
Santoni M, Monteiro FSM, Massari F, Abahssain H, Aurilio G, Molina-Cerrillo J, Myint ZW, Zabalza IO, Battelli N, Grande E. Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival. Crit Rev Oncol Hematol. 2022 Aug; 176:103731.

View in: PubMed
Rizzo A, Mollica V, Santoni M, Massari F. Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: a?meta-analysis. Immunotherapy. 2022 06; 14(8):617-625.

View in: PubMed
Santoni M, Massari F, Bracarda S, Grande E, Matrana MR, Rizzo M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A, Molina-Cerrillo J, Mollica V, Rizzo A, Battelli N. Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. Eur Urol Focus. 2022 11; 8(6):1696-1702.

View in: PubMed
Santoni M, Aurilio G, Massari F, Grande E, Matrana MR, Rizzo M, De Giorgi U, Incorvaia L, Martignetti A, Molina-Cerrillo J, Zabalza IO, Mollica V, Rizzo A, Battelli N, Porta C. Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison. Clin Genitourin Cancer. 2022 06; 20(3):285-295.

View in: PubMed
Rizzo A, Mollica V, Santoni M, Rosellini M, Marchetti A, Massari F. Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials. Future Oncol. 2022 Feb; 18(5):625-634.

View in: PubMed
Mollica V, Santoni M, Matrana MR, Basso U, De Giorgi U, Rizzo A, Maruzzo M, Marchetti A, Rosellini M, Bleve S, Maslov D, Tawagi K, Philon E, Blake Z, Massari F. Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma. Target Oncol. 2022 01; 17(1):61-68.

View in: PubMed

People

Explore

Similar Concepts

Top Journals